Edwards Lifesciences
USA
Transcatheter Mitral & Tricuspid Therapies (TMTT) are the future of Edwards – Estimated to be a more than $5 billion opportunity by 2028, Edwards will discuss its multiple transcatheter programs aimed at transforming care for the many patients suffering from mitral and tricuspid regurgitation. The Field Clinical Specialist TMTT is responsible for educating physicians on our technologies, device handling, implantation and troubleshooting techniques and case support. Territories: mainly Turkey & CEE (travelling required) You will make an impact by... Providing education on all aspects on one technology of the device, device handling, implantation and troubleshooting techniques related to equipment, tools and products required for device implants including full certification for independent case support Educating and training physicians, hospital personnel and hospital staff on all aspects of technical matters related to products and procedures...